在三阴性乳腺癌中选择性抑制CDK9
Ebtihal H Mustafa1, Geraldine Laven-Law1, Zoya Kikhtyak1
1Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
一种新的选择性循环素依赖性激酶9 (CDK9) 抑制剂CDDD11-8,有效向三阴性乳腺癌 (TNBC) 细胞和瘤. 这种有前途的疗法在TNBC亚型中显示出有效性,在临床前模型中没有观察到毒性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 三重阴性乳腺癌 (TNBC) 由于其固有的瘤异质性, presents一个重要的治疗挑战.
- TNBC瘤表现出对转录的依赖性,使得转录调节者如循环林依赖激酶9 (CDK9) 成为潜在的治疗标.
研究的目的:
- 在三阴性乳腺癌模型中预临床评估一种名为CDDD11-8的新型选择性CDK9抑制剂的疗效和机制.
主要方法:
- 利用了TNBC细胞系,患者衍生的有机体和患者衍生的解释模型进行体外和体外试验.
- 评估了增殖抑制,细胞循环停止,细胞亡和目标CDK9抑制 (RNAPII酸化,MYC/MCL1下调).
- 使用TNBC异种移植模型评估体内疗效,并评估小鼠和人类乳腺组织的毒性.
主要成果:
- CDDD11-8在TNBC细胞系和患者衍生器官 (IC50范围:272-771 nM) 中显示出剂量依赖的增殖抑制和诱导的亡.
- 证实了CDK9的目标抑制,导致MYC和MCL1瘤基因表达减少和RNAPII在基因促销者处暂停.
- 口服CDDD11-8在体内有效抑制TNBC异种移植瘤的生长,没有显著的毒性.
结论:
- CDK9代表了三阴性乳腺癌的可行的治疗标.
- 新型选择性CDK9抑制剂CDDD11-8在各种TNBC模型中表现出显著的临床前疗效,包括化疗耐药和转移性亚型.
- CDDD11-8显示出作为TNBC安全有效的向治疗的潜力.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
Published on: September 26, 2019
相关概念视频
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Negative Regulator Molecules
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
